跳至主要内容
临床试验/NCT00381316
NCT00381316已完成4 期

Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches

GE Healthcare1 个研究点 分布在 1 个国家目标入组 291 人开始时间: 2006年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
GE Healthcare
入组人数
291
试验地点
1
主要终点
The diagnostic results ("normal" versus "abnormal") of the dual-isotope and single isotope myocardial SPECT examinations will be compared for equivalence on a subject level for the Uninformed and Informed Analysis Groups.

研究概览

简要总结

The study is designed to determine whether a dual isotope protocol is equivalent to a single isotope in the diagnosis of myocardial ischemia and infarction using MYOVIEW SPECT imaging.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject is 18 years old or older.
  • Male subjects or non-lactating female subjects, who are either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or for women of childbearing potential, the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening within 24 hours before dosing (with the result known before investigational medicinal product administration) must be negative.
  • The subject is able and willing to comply with study procedures (i.e., 1 SPECT imaging at Stress, 2 SPECT imagings at Rest) and signed and dated informed consent is obtained.
  • The subject is suspected of or known of having CAD based on the subject's clinical signs, symptoms, or examinations .
  • The subject is referred for Rest/Stress (exercise or pharmacological) MPS-SPECT for known or suspected CAD (as clinically required).

排除标准

  • The subject was previously included in this study.
  • The subject received an IMP within 30 days before or is scheduled to receive one during or in the next 30 days after IMP administration.
  • The subject has known allergies to any product used in this study or its constituents, including subjects who are not able to exercise and have contraindications to Adenosine (e.g., Asthmatics).
  • The subject presents any clinically active, serious, life-threatening disease, with a life expectancy of less than 1 month.
  • The subject has no contraindications to any of the study procedures (e.g. physical exercise) or the involved drugs (Myoview, Thallium-201, Adenosine or Dipyridamole) such as e.g. 2nd or 3rd degree AV-block, SS syndrome, bradycardia, bronchoconstrictive or bronchospastic lung disease.

研究组 & 干预措施

1

Active Comparator

Thallous Chloride T1-201

干预措施: Thallous Chloride T1-201 (Drug)

2

Active Comparator

Technetium Tc99m Tetrofosmin injections

干预措施: Technetium Tc99m Tetrofosmin injections (Drug)

结局指标

主要结局

The diagnostic results ("normal" versus "abnormal") of the dual-isotope and single isotope myocardial SPECT examinations will be compared for equivalence on a subject level for the Uninformed and Informed Analysis Groups.

次要结局

未报告次要终点

研究者

发起方
GE Healthcare
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验